United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary FOUR-YEAR PATIENT FOLLOW-UP DATA SUPPORT SAFETY AND EFFECTIVENESS OF ENDOLOGIX’S POWERLINK SYSTEM
Three presentations highlight Powerlink at the International Congress XIX on Endovascular Interventions
View HTML
Toggle Summary ENDOLOGIX ANNOUNCES 2005 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS CONFERENCE CALL
ENDOLOGIX ANNOUNCES 2005 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS CONFERENCE CALL IRVINE, Calif. (February 15, 2006) – Endologix, Inc. (Nasdaq: ELGX) , the developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced
View HTML
Toggle Summary ENDOLOGIX APPROVED TO MANUFACTURE POWERLINK SYSTEM AT NEW FACILITY
Company’s Voluntary Limited Recall Completed; Corrective Action Implemented
View HTML
Toggle Summary ENDOLOGIX COMMENDS PRESIDENT BUSH, CONGRESS ON ENACTING THE SAAAVE ACT
ENDOLOGIX COMMENDS PRESIDENT BUSH, CONGRESS ON ENACTING THE SAAAVE ACT IRVINE, Calif. (February 9, 2006) – Endologix, Inc. (Nasdaq: ELGX) today called the Screening Abdominal Aortic Aneurysms Very Efficiently (SAAAVE) Act "an important piece of legislation designed to address a neglected and
View HTML
Toggle Summary ENDOLOGIX ANNOUNCES LIMITED VOLUNTARY RECALL OF POWERLINK SYSTEM DELIVERY CATHETER
Recall Does Not Involve Devices Implanted in Patients; Scheduled Procedures Continuing As Planned
View HTML
Toggle Summary FOUR-YEAR PATIENT FOLLOW-UP DATA SUPPORT DURABILITY OF ENDOLOGIX’S POWERLINK SYSTEM
FOUR-YEAR PATIENT FOLLOW-UP DATA SUPPORT DURABILITY OF ENDOLOGIX’S POWERLINK SYSTEM IRVINE, Calif. (November 21, 2005) – Endologix, Inc. (Nasdaq: ELGX) today announced that four-year patient follow-up data from the Company’s Powerlink® System pivotal clinical trial support
View HTML
Toggle Summary VEITH SYMPOSIUM PRESENTATIONS HIGHLIGHT ENDOLOGIX’S POWERLINK SYSTEM
VEITH SYMPOSIUM PRESENTATIONS HIGHLIGHT ENDOLOGIX’S POWERLINK SYSTEM IRVINE, Calif. (November 11, 2005) – Endologix, Inc. (Nasdaq: ELGX) today announced that two presentations at the 32nd Annual VEITH symposium™ will highlight the Company’s minimally invasive treatment for
View HTML
Toggle Summary ENDOLOGIX ANNOUNCES FIRST PATIENTS TREATED IN POWERLINK TRIAL WITH 34 MILLIMETER DIAMETER INFRARENAL CUFF
ENDOLOGIX ANNOUNCES FIRST PATIENTS TREATED IN POWERLINK TRIAL WITH 34 MILLIMETER DIAMETER INFRARENAL CUFF ENDOLOGIX ANNOUNCES FIRST PATIENTS TREATED IN POWERLINK TRIAL WITH 34 MILLIMETER DIAMETER INFRARENAL CUFF IRVINE, Calif. (October 10, 2005) – Endologix, Inc.
View HTML
Toggle Summary ENDOLOGIX ANNOUNCES FIRST PATIENT TREATED IN POWERLINK TRIAL FOR LARGE DIAMETER ANEURYSM NECKS
ENDOLOGIX ANNOUNCES FIRST PATIENT TREATED IN POWERLINK TRIAL FOR LARGE DIAMETER ANEURYSM NECKS ENDOLOGIX ANNOUNCES FIRST PATIENT TREATED IN POWERLINK TRIAL FOR LARGE DIAMETER ANEURYSM NECKS IRVINE, Calif. (September 28, 2005) – Endologix, Inc. (Nasdaq: ELGX) today announced that the first
View HTML
Toggle Summary ENDOLOGIX TO PRESENT AT UBS GLOBAL LIFE SCIENCES CONFERENCE
ENDOLOGIX TO PRESENT AT UBS GLOBAL LIFE SCIENCES CONFERENCE IRVINE, Calif. (September 22, 2005) – Endologix, Inc. (Nasdaq: ELGX) today announced that Paul McCormick, president and chief executive officer, will make a presentation to the investment community at the UBS Global Life Sciences
View HTML
Toggle Summary ENDOLOGIX REPORTS 2005 SECOND QUARTER RESULTS
Conference Call to Begin at 5:00 p.m. ET/2:00 p.m. PT Today
View HTML
Toggle Summary ENDOLOGIX APPROVED TO CONDUCT POWERLINK CLINICAL TRIALS ON PATIENTS WITH LARGE DIAMETER ANEURYSM NECKS
ENDOLOGIX APPROVED TO CONDUCT POWERLINK CLINICAL TRIALS ON PATIENTS WITH LARGE DIAMETER ANEURYSM NECKS IRVINE, Calif. (July 26, 2005) – Endologix, Inc. (Nasdaq: ELGX) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to enroll patients in its
View HTML
Toggle Summary ENDOLOGIX ANNOUNCES 2005 SECOND QUARTER FINANCIAL RESULTS CONFERENCE CALL
ENDOLOGIX ANNOUNCES 2005 SECOND QUARTER FINANCIAL RESULTS CONFERENCE CALL Irvine, Calif. – July 21, 2005 – Endologix, Inc. (Nasdaq: ELGX) , the developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that the
View HTML
Toggle Summary ENDOLOGIX COMPLETES $16.6 MILLION PRIVATE PLACEMENT
ENDOLOGIX COMPLETES $16.6 MILLION PRIVATE PLACEMENT Irvine, Calif. – July 8, 2005 – Endologix, Inc. (Nasdaq: ELGX) , developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced the completion of a previously announced
View HTML
Toggle Summary ENDOLOGIX ANNOUNCES $16.6 MILLION PRIVATE PLACEMENT
ENDOLOGIX ANNOUNCES $16.6 MILLION PRIVATE PLACEMENT Irvine, Calif. – July 6, 2005 – Endologix, Inc. (Nasdaq: ELGX), the developer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that it has signed definitive
View HTML